| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/03/2002 | CA2415236A1 Novispirins: antimicrobial peptides |
| 01/03/2002 | CA2414409A1 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | CA2414401A1 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | CA2414389A1 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | CA2414303A1 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | CA2414098A1 Human site-1 protease promoter |
| 01/03/2002 | CA2413747A1 Mammal 2p domain mechano-sensitive k+ channel, cloning and applications thereof |
| 01/03/2002 | CA2413742A1 Prion-binding activity in serum and proteins |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413673A1 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | CA2413545A1 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | CA2413417A1 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/03/2002 | CA2413338A1 Protein mixtures for wound healing |
| 01/03/2002 | CA2413209A1 Modulation of a.beta. levels by .beta.-secretase bace2 |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412612A1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | CA2381338A1 Human lyases |
| 01/02/2002 | WO2002098412A1 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 01/02/2002 | EP1167972A2 Enzyme catalyzed therapeutic agents |
| 01/02/2002 | EP1167390A1 Crystals and structural coordinate of protein complex and utilisation of the structural coordinate |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1166801A1 Preparations containing silicon dioxide to improve the taste thereof |
| 01/02/2002 | EP1166800A1 Pharmaceutical compositions containing antibiotics and fructan mixtures |
| 01/02/2002 | EP1166799A1 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) |
| 01/02/2002 | EP1166798A1 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use |
| 01/02/2002 | EP1166794A2 Method of treating retained pulmonary secretions |
| 01/02/2002 | EP1166792A2 Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use |
| 01/02/2002 | EP1166787A2 Stable amino acid based bicarbonate solutions for peritoneal dialysis and hemodialysis |
| 01/02/2002 | EP1166778A2 The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/02/2002 | EP1166765A2 Process for protecting human skin |
| 01/02/2002 | EP1166117A2 Diagnosis and treatment of multiple sclerosis |
| 01/02/2002 | EP1166102A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165818A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/02/2002 | EP1165805A1 Dsp-2 dual-specificity map kinase phosphatase |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165787A2 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 01/02/2002 | EP1165778A2 Casb618 polynucleotides and polypeptides and their use |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165774A2 Casb619 involved in colon cancers |
| 01/02/2002 | EP1165761A2 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/02/2002 | EP1165614A1 Antibodies against phosphomannan that are protective against candidiasis |
| 01/02/2002 | EP1165609A2 Human beta-secretase enzyme, inhibitors and their compositions and uses |
| 01/02/2002 | EP1165603A1 Human neurogenin 3-encoding nucleotide sequences |
| 01/02/2002 | EP1165597A1 Bifunctional molecules for delivery of therapeutics |
| 01/02/2002 | EP1165576A1 Process for preparing amine platinum complexes |
| 01/02/2002 | EP1165541A1 Dimeric compounds and as inhibitors of neuraminidase |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165184A2 Estrogen receptor-beta antagonism and bone diseases |
| 01/02/2002 | EP1165139A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor |
| 01/02/2002 | EP1165138A1 Method for a programmed controlled ovarian stimulation protocol |
| 01/02/2002 | EP1165137A1 Sphingomyelin containing preparation for the enhancement of tumor therapy |
| 01/02/2002 | EP1165136A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
| 01/02/2002 | EP1165135A1 Method of affecting cholesterol catabolism using nucear bile acid receptor |
| 01/02/2002 | EP1165127A2 Multivalent dengue virus vaccine |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165112A1 Modulators of polysaccharides and uses thereof |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165108A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 01/02/2002 | EP1165096A2 Use of cytidine derivatives for the treatment of leukaemia |
| 01/02/2002 | EP1165095A1 Agents for intravitreal administration to treat or prevent disorders of the eye |
| 01/02/2002 | EP1165090A2 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 01/02/2002 | EP1165088A1 Use of vasopeptidase inhibitors to treat angina pectoris |
| 01/02/2002 | EP1165086A2 Bupropion metabolites and methods of their synthesis and use |
| 01/02/2002 | EP1165083A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 01/02/2002 | EP1165080A2 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 01/02/2002 | EP1165079A2 Improved dialysis solutions and methods |
| 01/02/2002 | EP1165078A1 Methods of inducing cancer cell death and tumor regression |
| 01/02/2002 | EP1165074A2 Viral treatment |
| 01/02/2002 | EP1165073A1 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165070A1 Thiadiazolyl urea or thiourea derivatitives for antiviral treatment |
| 01/02/2002 | EP1165069A1 Antitumour synergistic composition |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 01/02/2002 | EP1165055A2 Pharmaceutical composition containing an extrusion additive |
| 01/02/2002 | EP1165054A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/02/2002 | EP1165041A1 Antimicrobial wipes which provide improved immediate germ reduction |
| 01/02/2002 | EP1164848A1 Compositions and methods for preventing and treating sexual dysfunctions |
| 01/02/2002 | EP1001801B1 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis |
| 01/02/2002 | EP0954314B1 Dosage forms for ameliorating male erectile dysfunction |
| 01/02/2002 | EP0877549A4 Methods and compositions for the reduction of xenotransplantation rejection |
| 01/02/2002 | CN1329674A A beta-peptide screeining methood |
| 01/02/2002 | CN1329613A New compounds |
| 01/02/2002 | CN1329508A Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 01/02/2002 | CN1329506A Formulation with an improved therapeutic range, cntainng nucleotide synthesis inhibitors |
| 01/02/2002 | CN1329505A Composition and method for treating allergic diseases |
| 01/02/2002 | CN1329504A F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 01/02/2002 | CN1329499A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 01/02/2002 | CN1329498A Cancer treatment composition and method using natural plant essential oils |
| 01/02/2002 | CN1329497A Cmbination therapy to treat hepatitis b virus |
| 01/02/2002 | CN1329496A Methods and cmpositions for prevention of tolerance to medications |
| 01/02/2002 | CN1329493A Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 01/02/2002 | CN1329490A Composition and method for treating allergic diseases |
| 01/02/2002 | CN1329488A Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
| 01/02/2002 | CN1329487A Dispersible compositions containing L-dopaethyl ester |
| 01/02/2002 | CN1328824A Compound for curing female sexual disorder |